As “Shrooms” Fix the World’s Largest Healthcare Crisis, This Tiny Stock Will Soar

Let me rattle off some sobering stats for you…

1 in 11 Canadians will have PTSD in their lifetime.

1 in 5 Canadians will suffer from addiction.

450,000 people worldwide died from drug use in 2015.

971 million people worldwide suffer from a mental or substance use disorder.

These statistics clearly illustrate two things:

  1. Mental health and substance abuse is a global epidemic.
  2. Current medications are failing to address this epidemic.

To that end, a breakthrough, novel therapy is needed to fix what may be the world’s biggest healthcare crisis.

That breakthrough therapy has finally arrived, and from the unlikeliest of places: psychedelics.

Yes. Those psychedelics. Magic mushrooms. LSD. MDMA. DMT.

As longtime readers know, a recent wave of academic research has discovered that these formerly-taboo drugs actually have immense therapeutic potential.

A pair of recent Johns Hopkins studies have found that the active ingredient in “magic mushrooms” (something called psilocybin) can significantly help with smoking cessation and reducing alcohol dependence.

An even more recent Johns Hopkins study published in 2020 found that psilocybin can relieve anxiety and depression levels in people with life-threatening cancer diagnoses four-times better than traditional antidepressants on the market.

That finding corroborates a previous NYU study, which found that psilocybin causes a “rapid and sustained” reduction in anxiety and depression levels in cancer patients. Meanwhile, a recent UC Davis study found that psychedelic micro-dosing can produce beneficial behavioral effects in patients with mental health disorders.

The list of academic studies goes on and on.

This groundbreaking research has coupled with shifting public perception (Netflix has released a flurry of pro-psychedelic movies over the past 12 months, highlighted by Have a Good Trip: Adventures in Psychedelics) and changing laws (On Election Day 2020, Washington D.C. and Oregon both passed measures to decriminalize/legalize psilocybin) to create foundation for a new class of superior psychedelic-inspired medicines to become the global treatment norm for mental health and substance abuse.

This is an investment megatrend that you don’t want to miss – and it all starts right now.

Today, we will give you one way to invest in this burgeoning “Shroom Boom.” It’s by buying stock in a small, completely off-the-radar psychedelic-assisted psychotherapy company that is the industry’s first-mover in Canada.

The First-Mover in Canada’s Psychedelics Market with Compelling Competitive Advantages

Numinus Wellness (OTCMKTS:LKYSF) is a $215 million integrated mental health company based in Canada that is focused on developing and delivering psychedelic-assisted psychotherapies to address various mental health and substance abuse disorders.

The first thing that stands out about Numinus is that this is a fully integrated and verticalized mental health company.

That is, Numinus researches these drugs in-house (through its Numinus Bioscience division), develops novel therapies in-house (through its Numinus R&D division), and facilitates these therapies to patients (through its Numinus Health division). Numinus is involved across the entire supply chain. It’s an end-to-end psychedelics company.

That’s important because of the second thing that stands out about Numinus: This is the first-mover in Canada’s psychedelics market.

The company’s Health Canada-licensed Bioscience lab has been operating since 2012. It is broadly considered the first psychedelics-focused research lab in Canada. Because of this, Numinus is the first public company in Canada to receive a license to produce and extract psilocybin from mushrooms.

As the first and only company with this license, Numinus is the first company to both partner with MAPS on Canada’s first compassionate access trial of MDMA for PTSD, and plunge head-first into Canada’s first compassionate trial of psilocybin for substance use disorders.

Meanwhile, as the leading company in psychedelics-inspired therapies research and testing, Numinus is also the leading company when it comes to commercializing and delivering these drugs. Through its Health division, Numinus is already actively supporting three clinics in administering ketamine-assisted psychotherapy.

Do you see the big picture here?

As the first-mover with an end-to-end integrated health platform, Numinus is developing huge competitive advantages in Canada’s psychedelics market.

This isn’t just the best psychedelics research company in Canada (which could be trumped by a more talented research team). It’s also the leading psychedelics drug developer, and the leading psychedelics therapy facilitator, too.

When you put all of that together… well, it’s tough to beat.

And, for that reason, we see Numinus Wellness as the highest-quality play on the “Shroom Boom” in Canada.

So, if you’re looking for another explosive shroom stock to potentially supercharge your portfolio, you should consider taking a position in Numinus Wellness stock today.

On the date of publication, Luke Lango did not have (either directly or indirectly) any positions in the securities mentioned in this article. 

The New Daily 10X Stock Report: 98.7% Accuracy — Gains Up to 466.78%. InvestorPlace’s brand-new and highly controversial newsletter… is rocking the industry… delivering one breakthrough stock recommendation each and every trading day… delivered straight to your inbox. 98.7% Accuracy to Date — Gains Up to 466.78%. Now for a limited time… you can get in for just $19. Click here to find out how.

Article printed from InvestorPlace Media,

©2023 InvestorPlace Media, LLC